Full-Time

Director – WW Medical Oncology

Thoracic Cancers

Posted on 5/8/2025

Deadline 8/1/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Compensation Overview

$207.5k - $251.4k/yr

+ Incentive Cash + Stock Opportunities

Senior, Expert

Company Historically Provides H1B Sponsorship

Uxbridge, UK + 1 more

More locations: Princeton, NJ, USA

HQ based position with international/domestic travel requirement approximately 20%.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Life sciences and/or healthcare professional training with an advanced degree is required (MD, PharmD, PhD).
  • Minimum of 5+ years working in the pharmaceutical industry (Medical Affairs/Medical Strategy, Clinical Research) with experience in Oncology therapeutic area is preferred.
  • Strong analytical skills, strong scientific data interpretation + contextualization and ability to work effectively with cross functional teams including clinical, commercialization, regulatory, HEOR and Access.
  • Excellent strategy development, critical thinking, decision making and demonstrated ability to successfully create and implement both short and long-range plans.
  • Entrepreneurial thinking, anticipates needs, assesses and manages business and organizational risks.
  • Highly organized and motivated and possess excellent people management, interpersonal, and strong communication skills, both verbal and written.
Responsibilities
  • Core member of the Asset/Indication Medical Strategy team, contributing to shaping global medical strategy with the cross functional team around key assets in scope.
  • Ensuring the asset/s are appropriately (co-)positioned and developed within the overall BMS disease area strategy in line with enterprise needs.
  • In line with Medical Product Leads and Disease Area Head direction, develop and execute the global medical strategy, scientific narratives, provide medical insight for Global Program Teams, commercial strategic plans, and provide strategic direction in medical communication efforts to ensure delivery of key knowledge to the internal stakeholders including local medical market colleagues; ensure alignment across global markets on medical strategy.
  • Responsible for developing asset/indication Integrated Evidence Plans - Lead workstreams to identify evidence gaps to address unmet needs and to define and support global execution of these opportunities. Develop prioritized Integrated Evidence Plans that conform to the Medical Value Framework for execution across modalities including Investigator sponsored research, Medical Affairs Sponsored Trials, RWD and Clinical Research Collaborations.
  • Collaborate with Medical Communications leads for the overall successful delivery of Global Medical Communications plans – Ensure workstreams are optimized in generating impactful strategies with respect to the medical communication plans including publications, scientific symposia, global independent medical education, internal training strategy as well as into commercialization brand plans.
  • Provide medical support for governance meetings, tumor CDTs and GPT, lead congresses execution, and advisory board meeting planning and execution; provide medical input for development of booths, congress materials, and standard response letters; and work with MedComms to support the execution of medcomms tactics (abstracts, manuscripts, and congress presentations).
  • Partner closely with medical colleagues in the Markets, with Clinical Research, Regulatory, Commercial, Access, Health Outcomes, Publications, and other key functions.
  • Cross collaborate with other disease area team members that have scope in tumor overlap to advise on development strategy as well as alignment overall with disease area strategy.
  • Provide program highlights/updates to Department and/or corporate leadership as requested.
  • Maintain ongoing long-term collaborative peer-to-peer relationships with key global thought leaders and oversight over activities, including Advisory Boards, congress encounters, symposia speaking engagements and alignment with markets/other cross functional partners to ensure efficient and impactful KOL collaboration.
  • Focus and engage with high impact external influencers/thought leaders to identify and translate key insights and to shape development of BMS pipeline.
  • Develop impactful managed access programs for pre-launch assets to ensure inclusive access to our medicines in a equitable manner globally, where permitted.
  • Ensure allocated budget and resources are appropriately spent to plan and consistent with business needs and in compliance with policies.
  • Ability to lead across teams and direct resources appropriately to manage the deliverables for the asset/indication across disease areas in alignment with GPT priorities.
Desired Qualifications
  • Experience in Oncology therapeutic area is preferred.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are then sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet the same quality and safety standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, as well as its commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing effective and affordable healthcare solutions while adhering to Environmental, Social, and Governance (ESG) standards.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with BioNTech enhances BMS's oncology portfolio against competitors like Merck.
  • Chris Shibutani's appointment may drive strategic growth and innovation at BMS.
  • $40 billion US investment shows BMS's commitment to long-term growth and innovation.

What critics are saying

  • Heavy reliance on real-world data may affect drug approval if data quality falters.
  • $11.1 billion BioNTech partnership could strain finances if results are underwhelming.
  • Recent layoffs may impact operational efficiency and employee morale at BMS.

What makes Bristol Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company integrates real-world data to enhance drug development and patient outcomes.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

ROI-NJ
Jun 13th, 2025
Bristol Myers Squibb Names Shibutani As Evp, Chief Strategy Officer

Bristol Myers Squibb (BMS) this week appointed Chris Shibutani as executive vice president, chief strategy officer, effective immediately. Shibutani’s role is a new position on the BMS leadership team. The announcement was made on a LinkedIn post.Shibutani will lead the development and advancement of the company’s long-term strategic plan, collaborating across the enterprise to drive innovation and growth. He brings more than 25 years of experience in the financial services industry covering global pharmaceutical, biotechnology and medical device industries.Prior to BMS, Shibutani served as managing director in the global investment research division at Goldman Sachs. Previous roles include senior analyst positions at Hambrecht & Quist, Cowen, UBS, and J.P. Morgan.Before his career in finance, Shibutani was a physician trained in anesthesiology and critical care medicine at Massachusetts General Hospital and practiced at Memorial Sloan Kettering Cancer Center

PharmaData
Jun 13th, 2025
Bristol Myers Squibb Highlights Targeted Protein Degradation Data, Including CELMoD Agents, at EHA 2025

Bristol Myers Squibb highlights targeted protein degradation advances, including CELMoD agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy.

Hit Consultant
Jun 10th, 2025
From Raw Records To Real-Time Insights: Climbing Pharma’S Real-World Data Maturity Curve

Viraj Narayanan, CEO at Cornerstone AI Daniel Lane, Head of RWD Strategy & Operations at Bristol Myers SquibbReal-world data (RWD) has become the pharmaceutical industry’s most promising yet challenging frontier. While companies have long recognized its potential to complement clinical trials and deepen patient outcome insights, many still struggle to fully realize its value.We’ve seen firsthand, from early discovery to market authorization to post-launch evidence generation, that extracting meaningful value from RWD requires more than just data acquisition. It demands a consistent, scalable, and repeatable approach to data quality, as well as a strategic roadmap that moves an organization from minimal use of RWD to a position of true leadership. This journey isn’t simple, but for those committed to navigating it, the competitive advantages are substantial. And, importantly, RWD holds the potential to help bring lifesaving and life-changing medications to market faster and safer than ever before.From Data Collection to MaturityPharma’s growing reliance on RWD has encouraged an influx of partnerships with data aggregators, medical institutions, and digital health platforms. Yet, not all companies are at the same level of maturity in using that data effectively

Devdiscourse
Jun 2nd, 2025
Reuters Health News Summary

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could take on rival Merck & Co's best-selling drug Keytruda.

The Motley Fool
Jun 2nd, 2025
Why BioNTech Stock Soared Today

BioNTech and Bristol Myers Squibb are teaming up to develop a new cancer drug, BNT327.

INACTIVE